scholarly journals 312 Development of an Integrated End-Stage Kidney Disease Care Coordination Model: A Randomized Controlled Trial Protocol

2020 ◽  
Vol 75 (4) ◽  
pp. 626-627
Keyword(s):  
Randomized Controlled Trial ◽  
Kidney Disease ◽  
Care Coordination ◽  
Controlled Trial ◽  
Trial Protocol ◽  
End Stage Kidney Disease ◽  
Coordination Model ◽  
Randomized Controlled ◽  
End Stage

scholarly journals Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease

2019 ◽  
Vol 4 (9) ◽  
pp. 1235-1247 ◽  
Author(s):  
Steven Fishbane ◽  
Bruce S. Spinowitz ◽  
Wayne A. Wisemandle ◽  
Nancy E. Martin
Keyword(s):  
Randomized Controlled Trial ◽  
Kidney Disease ◽  
Controlled Trial ◽  
Epoetin Alfa ◽  
End Stage Kidney Disease ◽  
Randomized Controlled ◽  
End Stage

scholarly journals Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial

2021 ◽  
Vol 11 ◽  
Author(s):  
Wei Mao ◽  
Nizhi Yang ◽  
Lei Zhang ◽  
Chuang Li ◽  
Yifan Wu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Randomized Controlled Trial ◽  
Kidney Disease ◽  
Serum Creatinine ◽  
Cardiovascular Events ◽  
Controlled Trial ◽  
Diabetic Patients ◽  
End Stage Kidney Disease ◽  
Randomized Controlled ◽  
End Stage

Chinese herbal medicine (CHM) might have benefits in patients with non-diabetic chronic kidney disease (CKD), but there is a lack of high-quality evidence, especially in CKD4. This study aimed to assess the efficacy and safety of Bupi Yishen Formula (BYF) vs. losartan in patients with non-diabetic CKD4. This trial was a multicenter, double-blind, double-dummy, randomized controlled trial that was carried out from 11-08-2011 to 07-20-2015. Patients were assigned (1:1) to receive either BYF or losartan for 48 weeks. The primary outcome was the change in the slope of the estimated glomerular filtration rate (eGFR) over 48 weeks. The secondary outcomes were the composite of end-stage kidney disease, death, doubling of serum creatinine, stroke, and cardiovascular events. A total of 567 patients were randomized to BYF (n = 283) or losartan (n = 284); of these, 549 (97%) patients were included in the final analysis. The BYF group had a slower renal function decline particularly prior to 12 weeks over the 48-week duration (between-group mean difference of eGFR slopes: −2.25 ml/min/1.73 m2/year, 95% confidence interval [CI]: −4.03,−0.47), and a lower risk of composite outcome of death from any cause, doubling of serum creatinine level, end-stage kidney disease (ESKD), stroke, or cardiovascular events (adjusted hazard ratio = 0.61, 95%CI: 0.44,0.85). No significant between-group differences were observed in the incidence of adverse events. We conclude that BYF might have renoprotective effects among non-diabetic patients with CKD4 in the first 12 weeks and over 48 weeks, but longer follow-up is required to evaluate the long-term effects.Clinical Trial Registration:http://www.chictr.org.cn, identifier ChiCTR-TRC-10001518.

Sign in / Sign up

Export Citation Format

Share Document